The global cell and gene therapy analytical testing market was valued at USD 1.43 billion in 2025. The market is estimated at USD 1.62 billion in 2026 and is projected to reach USD 5.72 billion by 2036, at a CAGR of 13.4% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering test methods, critical quality attributes by product type, testing cost and turnaround, the pipeline and approval landscape, regulatory frameworks, pricing, the provider landscape, and growth opportunities.
The market includes the testing services, assay development, and validation work used to characterize, release, and monitor the stability of cell and gene therapy products. Covered work spans safety, potency, identity, purity, genome-editing, and stability testing at the raw material, in-process, release, and post-approval stages. Manufacturing services, test instruments and reagents, preclinical toxicology, and patient sample testing are excluded.
Testing absorbs more of the cost and development time of these products than it does for conventional biologics, because many batches are made for one patient, must be used within days, and a defective lot can cause severe and often irreversible harm. Demand in the cell and gene therapy analytical testing market therefore tracks the pipeline closely. A pipeline review released in January 2026 counted six products with FDA decision dates in 2026 and 18 more expected in 2027, 12 of them in Phase 3. In July 2026, the FDA widened the label of CASGEVY, the first CRISPR-based therapy, to patients as young as two, and the therapy is offered at more than 75 authorized U.S. treatment centers.
Much of the pipeline sits with small and mid-sized biotech firms that depend on venture and public funding, so program cuts or failed financings can remove testing demand suddenly. Charles River Laboratories reported second-quarter 2026 Discovery and Safety Assessment revenue of USD 606.5 million, down 1.9% year over year, while raising its full-year organic growth guidance, which suggests outsourced testing demand is stabilizing after a downturn. A shortage of scientists experienced in advanced therapy analytics limits how fast capacity can be added. Further challenges include the lack of reference materials and standards, variability between laboratories running similar cell-based assays, and the difficulty of completing a full test panel before an autologous product must be given to the patient.
Potency and functional assay development is the largest opportunity, as regulators want assays that measure the biological activity behind the clinical effect and potency gaps are a common cause of approval delays. Genome-editing analytics offer another opening, supported by FDA draft guidance issued in June 2026 that lets sponsors of editing products draw on published and platform data in place of repeating studies when they can justify it. Rapid microbiological and automated methods address the conflict between 14-day sterility testing and products with very short shelf lives, and commercial lot release creates recurring revenue as the approved product base grows. Key trends include the move from fixed requirements to data-justified flexibility, platform-based development with reusable characterization packages, and closer integration of testing with manufacturing and in-process control.
By test type, the cell and gene therapy analytical testing market is segmented into safety testing, potency & functional testing (P&F), identity testing, purity & impurity testing (including capsid and vector copy analysis), genome-editing specific analysis, and stability & comparability testing. In 2026, safety testing is expected to hold the largest share, as sterility, mycoplasma, endotoxin, and viral safety checks apply to every batch at several stages, and vector-based products need a broad viral panel. Potency & functional testing is expected to grow at the highest CAGR, because regulators want potency tied to the mechanism of action, each assay is product-specific, and weak potency data often delay approvals. Genome-editing specific analysis covers attributes, such as off-target editing, that have no equivalent in conventional biologics testing.
By therapy type, the cell and gene therapy analytical testing market is segmented into cell therapy, gene therapy (viral and non-viral), genome-edited therapy, and other advanced therapies, with cell therapy split into autologous and allogeneic products. Gene therapy is expected to lead in 2026, given the wide test panels vector-based products need, from capsid ratio and copy number to transgene expression, and the many rare disease gene therapies nearing registration. Genome-edited therapy is expected to grow at the highest CAGR, supported by the approval and expanding use of CRISPR-based treatment, the number of editing programs moving through the clinic, and analytical needs such as off-target assessment and detection of structural changes that have no counterpart in conventional gene therapy. Autologous cell therapies, made for one patient and used within days, face the tightest turnaround demands.
By development phase, the cell and gene therapy analytical testing market is segmented into preclinical & early clinical, late clinical (pre-registration), and commercial & post-approval. Late clinical work is expected to hold the largest share in 2026, because the period before registration is when methods must be fully validated, comparability must be shown across every manufacturing change, and stability programs must be set up, making it the most testing-intensive stage of a product's life. Commercial & post-approval testing is expected to grow at the highest CAGR, as more approved products need release testing for every lot, approvals extend to new patient groups and countries, and post-approval commitments add long-term stability and monitoring.
By service model, the cell and gene therapy analytical testing market is segmented into outsourced testing services, covering routine release, method development, and characterization work, and in-house testing. Outsourced testing services are expected to hold the largest share in 2026 and also to grow at the highest CAGR, since building accredited advanced therapy testing capability is a fixed cost few developers can justify for one program, regulatory experience is concentrated among specialist providers, and the many small and mid-sized developers in the pipeline outsource out of necessity. In-house testing keeps a role at large pharmaceutical companies with several programs, at hospital and academic manufacturing units, and for in-process controls that must be run at the point of manufacture.
By end user, the cell and gene therapy analytical testing market is segmented into cell & gene therapy developers (pharma and biotech), CDMOs, academic & hospital manufacturing units, and other end users. Developers are expected to hold the largest share in 2026, as they are responsible for product quality and regulatory filings and therefore buy the testing, whether it is done internally or contracted out. CDMOs are expected to grow at the highest CAGR, as they bundle testing with manufacturing, continue to invest in cell and gene therapy capacity, and appeal to developers that want one partner responsible for both production and quality. Lonza, for example, reported first-half 2026 sales growth of 16.0% at constant exchange rates while continuing to invest in cell and gene therapy facilities.
In 2026, North America is expected to hold the largest share of the cell and gene therapy analytical testing market, as the region has the highest concentration of developers and clinical programs, FDA expectations shape analytical practice worldwide, major contract testing organizations such as Charles River Laboratories and Labcorp are based there, and the number of approved products drives commercial release testing. Europe holds a significant share, backed by broad advanced therapy development, testing capacity at providers such as Lonza, SGS, Eurofins Scientific, and Sartorius, and EU rules for advanced therapy medicinal products, and hospital and academic production units play a bigger part there than in North America.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by a surge of advanced therapy programs in China, Japan, and South Korea, including many CAR-T candidates in China, strong government funding for advanced therapy capability, growing regional testing and manufacturing capacity such as WuXi AppTec, and lower testing costs for programs developed elsewhere. Latin America and the Middle East & Africa hold smaller shares, with clinical activity in Brazil supporting modest demand and Gulf investment in advanced therapy centers, including for hemoglobin disorders common in the region, supporting growth from a small base.
Revenue in the cell and gene therapy analytical testing market sits mainly with a group of large contract testing organizations and CDMOs, while specialist firms hold positions in areas such as potency assay development, vector characterization, and genome-editing analysis. Providers compete on complete release panels, inspection records, turnaround time, and support from early development through commercial supply. Leading companies are expanding advanced therapy test capacity, introducing faster release methods, deepening potency and gene-editing know-how, and pairing testing with manufacturing services. Recent developments include Lonza's raised margin guidance and new cell and gene therapy facilities, and steadier outsourced testing demand at Charles River Laboratories.
Key companies profiled in the report include Charles River Laboratories International, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), WuXi AppTec Co., Ltd. (China), Lonza Group AG (Switzerland), SGS SA (Switzerland), Eurofins Scientific SE (Luxembourg), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), and Bio-Techne Corporation (U.S.).
The market includes the testing services, assay development, and validation work used to characterize, release, and monitor the stability of cell and gene therapy products. Covered work spans safety, potency, identity, purity, genome-editing, and stability testing at the raw material, in-process, release, and post-approval stages. Manufacturing services, test instruments and reagents, preclinical toxicology, and patient sample testing are excluded.
Testing absorbs more of the cost and development time of these products than it does for conventional biologics, because many batches are made for one patient, must be used within days, and a defective lot can cause severe and often irreversible harm. Demand in the cell and gene therapy analytical testing market therefore tracks the pipeline closely. A pipeline review released in January 2026 counted six products with FDA decision dates in 2026 and 18 more expected in 2027, 12 of them in Phase 3. In July 2026, the FDA widened the label of CASGEVY, the first CRISPR-based therapy, to patients as young as two, and the therapy is offered at more than 75 authorized U.S. treatment centers.
Market Dynamics
Growth in the cell and gene therapy analytical testing market is driven by the expanding clinical pipeline and the rising number of products reaching registration, as each filing needs validated methods, comparability data for every process change, and a stability program, and each approved product then needs release testing for every commercial lot. These complex, single-dose products also carry an unusually heavy testing load. Most developers outsource because accredited facilities and expert staff are too costly to build for one program. Shifting regulatory expectations add work as well: in May 2026, the FDA's Center for Biologics Evaluation and Research issued final guidance dropping the fixed three-lot process performance qualification requirement and allowing concurrent validation and release, which places more weight on strong comparability data.Much of the pipeline sits with small and mid-sized biotech firms that depend on venture and public funding, so program cuts or failed financings can remove testing demand suddenly. Charles River Laboratories reported second-quarter 2026 Discovery and Safety Assessment revenue of USD 606.5 million, down 1.9% year over year, while raising its full-year organic growth guidance, which suggests outsourced testing demand is stabilizing after a downturn. A shortage of scientists experienced in advanced therapy analytics limits how fast capacity can be added. Further challenges include the lack of reference materials and standards, variability between laboratories running similar cell-based assays, and the difficulty of completing a full test panel before an autologous product must be given to the patient.
Potency and functional assay development is the largest opportunity, as regulators want assays that measure the biological activity behind the clinical effect and potency gaps are a common cause of approval delays. Genome-editing analytics offer another opening, supported by FDA draft guidance issued in June 2026 that lets sponsors of editing products draw on published and platform data in place of repeating studies when they can justify it. Rapid microbiological and automated methods address the conflict between 14-day sterility testing and products with very short shelf lives, and commercial lot release creates recurring revenue as the approved product base grows. Key trends include the move from fixed requirements to data-justified flexibility, platform-based development with reusable characterization packages, and closer integration of testing with manufacturing and in-process control.
Segment Analysis
The report analyzes the market by test type, therapy type, development phase, service model, end user, and geography, helping stakeholders identify the most attractive areas for service investment, partnering, and business development.By test type, the cell and gene therapy analytical testing market is segmented into safety testing, potency & functional testing (P&F), identity testing, purity & impurity testing (including capsid and vector copy analysis), genome-editing specific analysis, and stability & comparability testing. In 2026, safety testing is expected to hold the largest share, as sterility, mycoplasma, endotoxin, and viral safety checks apply to every batch at several stages, and vector-based products need a broad viral panel. Potency & functional testing is expected to grow at the highest CAGR, because regulators want potency tied to the mechanism of action, each assay is product-specific, and weak potency data often delay approvals. Genome-editing specific analysis covers attributes, such as off-target editing, that have no equivalent in conventional biologics testing.
By therapy type, the cell and gene therapy analytical testing market is segmented into cell therapy, gene therapy (viral and non-viral), genome-edited therapy, and other advanced therapies, with cell therapy split into autologous and allogeneic products. Gene therapy is expected to lead in 2026, given the wide test panels vector-based products need, from capsid ratio and copy number to transgene expression, and the many rare disease gene therapies nearing registration. Genome-edited therapy is expected to grow at the highest CAGR, supported by the approval and expanding use of CRISPR-based treatment, the number of editing programs moving through the clinic, and analytical needs such as off-target assessment and detection of structural changes that have no counterpart in conventional gene therapy. Autologous cell therapies, made for one patient and used within days, face the tightest turnaround demands.
By development phase, the cell and gene therapy analytical testing market is segmented into preclinical & early clinical, late clinical (pre-registration), and commercial & post-approval. Late clinical work is expected to hold the largest share in 2026, because the period before registration is when methods must be fully validated, comparability must be shown across every manufacturing change, and stability programs must be set up, making it the most testing-intensive stage of a product's life. Commercial & post-approval testing is expected to grow at the highest CAGR, as more approved products need release testing for every lot, approvals extend to new patient groups and countries, and post-approval commitments add long-term stability and monitoring.
By service model, the cell and gene therapy analytical testing market is segmented into outsourced testing services, covering routine release, method development, and characterization work, and in-house testing. Outsourced testing services are expected to hold the largest share in 2026 and also to grow at the highest CAGR, since building accredited advanced therapy testing capability is a fixed cost few developers can justify for one program, regulatory experience is concentrated among specialist providers, and the many small and mid-sized developers in the pipeline outsource out of necessity. In-house testing keeps a role at large pharmaceutical companies with several programs, at hospital and academic manufacturing units, and for in-process controls that must be run at the point of manufacture.
By end user, the cell and gene therapy analytical testing market is segmented into cell & gene therapy developers (pharma and biotech), CDMOs, academic & hospital manufacturing units, and other end users. Developers are expected to hold the largest share in 2026, as they are responsible for product quality and regulatory filings and therefore buy the testing, whether it is done internally or contracted out. CDMOs are expected to grow at the highest CAGR, as they bundle testing with manufacturing, continue to invest in cell and gene therapy capacity, and appeal to developers that want one partner responsible for both production and quality. Lonza, for example, reported first-half 2026 sales growth of 16.0% at constant exchange rates while continuing to invest in cell and gene therapy facilities.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America, spanning 17 countries and four rest-of-region groups. The regional analysis of the cell and gene therapy analytical testing market considers developer and clinical trial activity, approved products, regulatory frameworks, contract testing capacity, and public investment in advanced therapies.In 2026, North America is expected to hold the largest share of the cell and gene therapy analytical testing market, as the region has the highest concentration of developers and clinical programs, FDA expectations shape analytical practice worldwide, major contract testing organizations such as Charles River Laboratories and Labcorp are based there, and the number of approved products drives commercial release testing. Europe holds a significant share, backed by broad advanced therapy development, testing capacity at providers such as Lonza, SGS, Eurofins Scientific, and Sartorius, and EU rules for advanced therapy medicinal products, and hospital and academic production units play a bigger part there than in North America.
Asia-Pacific is expected to grow at the highest CAGR during the forecast period, driven by a surge of advanced therapy programs in China, Japan, and South Korea, including many CAR-T candidates in China, strong government funding for advanced therapy capability, growing regional testing and manufacturing capacity such as WuXi AppTec, and lower testing costs for programs developed elsewhere. Latin America and the Middle East & Africa hold smaller shares, with clinical activity in Brazil supporting modest demand and Gulf investment in advanced therapy centers, including for hemoglobin disorders common in the region, supporting growth from a small base.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard (market leaders, market differentiators, vanguards, and emerging players), and market share/rank analysis by key player for 2025. Company profiles include business and financial overviews, analytical service portfolios, capacity and footprint, regulatory track records, strategic developments, and SWOT analyses.Revenue in the cell and gene therapy analytical testing market sits mainly with a group of large contract testing organizations and CDMOs, while specialist firms hold positions in areas such as potency assay development, vector characterization, and genome-editing analysis. Providers compete on complete release panels, inspection records, turnaround time, and support from early development through commercial supply. Leading companies are expanding advanced therapy test capacity, introducing faster release methods, deepening potency and gene-editing know-how, and pairing testing with manufacturing services. Recent developments include Lonza's raised margin guidance and new cell and gene therapy facilities, and steadier outsourced testing demand at Charles River Laboratories.
Key companies profiled in the report include Charles River Laboratories International, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), WuXi AppTec Co., Ltd. (China), Lonza Group AG (Switzerland), SGS SA (Switzerland), Eurofins Scientific SE (Luxembourg), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), and Bio-Techne Corporation (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global cell and gene therapy analytical testing market.
- Explains how pipeline growth, commercial approvals, outsourcing, and new FDA guidance are shaping testing demand.
- Assesses the impact of developer funding volatility, staff shortages, missing reference standards, and short product shelf lives.
- Identifies high-growth opportunities across test type, therapy type, development phase, service model, end user, and region.
- Tracks potency assay development, genome-editing analytics, and rapid and automated release methods.
- Benchmarks leading providers on test panel breadth, regulatory track record, capacity, turnaround, and strategic developments.
- Supports service planning, capacity investment, partnering, and outsourcing decisions for testing providers, CDMOs, therapy developers, and investors.
Key Questions Answered
- How big is the global cell and gene therapy analytical testing market today, and how will it grow through 2036?
- How does the number of products reaching registration and approval affect testing demand?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- Why is potency testing the main analytical bottleneck, and how are providers addressing it?
- How will FDA guidance on process validation and knowledge leveraging change testing requirements?
- Which test types, therapy types, development phases, service models, and end users will grow the fastest?
- How are rapid and automated methods resolving the conflict between testing time and short shelf lives?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading testing providers, and how do they compare on capabilities, capacity, and regulatory record?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Cell and Gene Therapy Analytical Testing Market Assessment, by Test Type
6. Cell and Gene Therapy Analytical Testing Market Assessment, by Therapy Type
7. Cell and Gene Therapy Analytical Testing Market Assessment, by Development Phase
8. Cell and Gene Therapy Analytical Testing Market Assessment, by Service Model
9. Cell and Gene Therapy Analytical Testing Market Assessment, by End User
10. Cell and Gene Therapy Analytical Testing Market Assessment, by Geography
11. Competition Analysis
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Charles River Laboratories International, Inc.
- Laboratory Corporation of America Holdings
- WuXi AppTec Co., Ltd.
- Lonza Group AG
- SGS SA
- Eurofins Scientific SE
- Sartorius AG
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Bio-Techne Corporation
